Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. : Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Out of 28...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Future oncology (London, England) England), 2020-07, Vol.16 (19), p.1371-1384
Hauptverfasser:	Kuppen, Malou Cp, Westgeest, Hans M, van der Doelen, Maarten J, van den Eertwegh, Alphonsus Jm, Coenen, Jules Llm, Aben, Katja Kh, van den Bergh, Alphons Cm, Bergman, Andries M, den Bosch, Joan van, Celik, Filiz, Hendriks, Mathijs P, Lavalaye, Jules, der Meer, Saskia van, Polee, Marco B, Somford, Diederik M, van Oort, Inge M, Uyl-de Groot, Carin A, Gerritsen, Winald R
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Bone Neoplasms - metabolism Bone Neoplasms - radiotherapy Bone Neoplasms - secondary Cancer therapies Databases, Factual Drug Administration Schedule Hemoglobin Humans Lymphatic system Male Metastasis metastatic castration-resistant prostate cancer Middle Aged Patients Prostate cancer Prostatic Neoplasms, Castration-Resistant - metabolism Prostatic Neoplasms, Castration-Resistant - pathology Prostatic Neoplasms, Castration-Resistant - radiotherapy Radioisotopes - administration & dosage Radium - administration & dosage radium-223 real-world outcomes Retrospective Studies sequencing skeletal-related events survival Survival Rate Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!